Novo Nordisk launched a multi-month Wegovy subscription program offering fixed monthly pricing through telehealth providers, aiming to improve affordability and long-term adherence among self-pay patients.
Novo Nordisk announced a subscription-based pricing model for its obesity therapy Wegovy.
Emerging Pharma Leaders nominations are now open!
Do you know someone who can make tough decisions that continue to face manufacturers? Are they destined to change the future of pharma?
Nominate a colleague with impressive leadership and career intentions – even yourself! – for the Pharmaceutical Executive 2026 Emerging Pharma Leaders Awards.
The decision marks a shift in how the company is approaching patient access and affordability in a rapidly expanding market for weight management treatments.
The new multi-month subscription program launched March 31, 2026 offers eligible self-pay patients a fixed monthly price for Wegovy through select telehealth providers, including Ro, WeightWatchers, LifeMD, and Hims & Hers, a company who Novo recently signed and
Novo’s initiative is designed to reduce cost variability and improve treatment adherence by providing predictable pricing over longer periods.
“The new Wegovy subscription program removes barriers, providing people who enroll a simple, affordable, and consistent way to start and stay on genuine, FDA-approved treatment,” said Ed Cinca, senior vice president of Marketing & Patient Solutions at Novo Nordisk. “By providing predictable monthly pricing, multi-month options, and access through trusted telehealth providers, this program aims to support a more manageable way for people to stay on treatment and focus on achieving meaningful, sustainable weight loss outcomes.”
Under the program, patients can enroll in three, six, or twelve-month plans, with longer commitments offering lower monthly costs.1 For the injectable formulation, pricing ranges from $329 per month for a three-month subscription to $249 per month for a 12-month plan, representing potential annual savings of up to $1,200.1
The oral formulation is priced slightly lower, with monthly costs decreasing from $289 to $249 depending on the subscription length, offering savings of up to $600 per year.
The move reflects growing pressure across the obesity treatment landscape to address affordability and persistence challenges, particularly among self-pay patients. While GLP-1 therapies such as semaglutide have demonstrated significant efficacy, high out-of-pocket costs have remained a barrier to sustained use.1
By introducing a subscription model, Novo Nordisk is attempting to create a more predictable cost structure that may support long-term adherence, an important factor given that obesity is widely recognized as a chronic condition requiring ongoing management.1
Wegovy remains available through more than 70,000 US pharmacies as well as NovoCare Pharmacy, and commercially insured patients may still qualify for existing savings programs that reduce monthly costs to as little as $25.2
The subscription offering is positioned as an alternative for patients without insurance coverage or those seeking more predictable pricing.
As competition intensifies in the GLP-1 market, with multiple pharmaceutical companies advancing both injectable and
Novo continues to expand its GLP-1 medication offerings to patients, as earlier this month FDA approved the company’s
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
